The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma

Jason Shafrin1 Precision Health Economics, Los Angeles, CA, USACorrespondence[email protected]

Jeffrey Sullivan1 Precision Health Economics, Los Angeles, CA, USA

Jacquelyn W Chou1 Precision Health Economics, Los Angeles, CA, USA

Michael N Neely2 Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

Justin F Doan3 Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA

J Ross Maclean1 Precision Health Economics, Los Angeles, CA, USA

Pages 731-739 | Published online: 29 Nov 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

National Cancer InstituteCommon cancer types Available from: https://www.cancer.gov/types/common-cancersAccessed November 6, 2017
Google Scholar
National Cancer InstituteCancer stat facts: kidney and renal pelvis cancer Available from: https://seer.cancer.gov/statfacts/html/kidrp.htmlAccessed November, 6, 2017
Google Scholar
American Cancer SocietyWhat is kidney cancer? Available from: https://www.cancer.org/cancer/kidney-cancer/about/what-is-kidney-cancer.htmlAccessed November 6, 2017
Google Scholar
ChittoriaNRiniBIRenal cell carcinoma Available from: www.cleve-landclinicmeded.com/medicalpubs/diseasemanagement/nephrology/renal-cell-carcinoma/Accessed November 6, 2017
Google Scholar
MinguetJSmithKHBramlageCPBramlagePTargeted therapies for treatment of renal cell carcinoma: recent advances and future perspectivesCancer Chemother Pharmacol201576221923325963382
PubMed Web of Science ®Google Scholar
LiuGFranssenEFitchMIWarnerEPatient preferences for oral versus intravenous palliative chemotherapyJ Clin Oncol19971511101158996131
PubMed Web of Science ®Google Scholar
MacleanJRPfisterMZhouZRoyATuomariVAHeifetsMQuantifying the impact of nonadherence patterns on exposure to oral immunosuppressantsTher Clin Risk Manag2011714915621691585
PubMed Web of Science ®Google Scholar
ByfieldSAMcPheetersJTBurtonTMNagarSPHackshawMDPersistence and compliance among US patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysisJ Manag Care Spec Pharm201521651552226011553
PubMed Web of Science ®Google Scholar
MargolisJPrincicNDoanJLenhartGMotzerRAnalysis of real world treatment compliance in a cohort of 2,395 patients with metastatic renal cell carcinoma (mRCC)ASCO Annu Meet Proc20153315 Suppl4546
Google Scholar
de Figueiredo JuniorAGForonesNMStudy on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancerArq Gastroenterol201451318619125296077
PubMedGoogle Scholar
PartridgeAHArcherLKornblithABAdherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104J Clin Oncol201028142418242220368559
PubMed Web of Science ®Google Scholar
WaterhouseDMCalzoneKAMeleCBrennerDEAdherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoringJ Clin Oncol1993116118911978501505
PubMed Web of Science ®Google Scholar
LevineAMRichardsonJLMarksGCompliance with oral drug therapy in patients with hematologic malignancyJ Clin Oncol198759146914763625261
PubMed Web of Science ®Google Scholar
PartridgeAHAvornJWangPSWinerEPAdherence to therapy with oral antineoplastic agentsJ Natl Cancer Inst200294965266111983753
PubMed Web of Science ®Google Scholar
SunMLarcherAKarakiewiczPIOptimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidenceInt J Nephrol Renovasc Dis2014740140725378943
PubMedGoogle Scholar
Afinitor (everolimus) [prescribing information]East Hanover, NJNovartis Pharmaceuticals Corporation2010
Google Scholar
Inlyta (axitinib) tablets [prescribing information]New York, NYPfizer Inc2012
Google Scholar
MoesDJPressRRden HartighJvan der StraatenTde FijterJWGuchelaarHJPopulation pharmacokinetics and pharmacogenet-ics of everolimus in renal transplant patientsClin Pharmacokinet201251746748022624503
PubMed Web of Science ®Google Scholar
NeelyMNvan GuilderMGYamadaWMSchumitzkyAJelliffeRWAccurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for RTher Drug Monit201234446747622722776
PubMed Web of Science ®Google Scholar
RiniBIMelicharBUedaTAxitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trialLancet Oncol201314121233124224140184
PubMed Web of Science ®Google Scholar
TortoriciMACohenEEPithavalaYKPharmacokinetics of single-agent axitinib across multiple solid tumor typesCancer Chemother Pharmacol20147461279128925336084
PubMed Web of Science ®Google Scholar
Agency for Healthcare Research and QualityMedical Expenditure Panel Survey (MEPS)Rockville, MDU.S. Department of Health and Human Services2012
Google Scholar
GarrettMPolandBBrennanMHeeBPithavalaYKAmanteaMAPopulation pharmacokinetic analysis of axitinib in healthy volunteersBr J Clin Pharmacol201477348049223834452
PubMed Web of Science ®Google Scholar
RavaudAUrvaSRGroschKCheungWKAnakOSellamiDBRelationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncologyEur J Cancer201450348649524332451
PubMed Web of Science ®Google Scholar
GeynismanDMWickershamKEAdherence to targeted oral anticancer medicationsDiscov Med2013158323124123636140
PubMed Web of Science ®Google Scholar
FoulonVSchöffskiPWolterPPatient adherence to oral anticancer drugs: an emerging issue in modern oncologyActa Clin Belg2011662859621630604
PubMed Web of Science ®Google Scholar
DanesiRBoniJPRavaudAOral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implicationsCancer Treat Rev201339778479223375248
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date